Bappaditya Dey BVSc&AH, MVSc, PhD Post-doctoral Fellow Center for Tuberculosis Research Division of Infectious Diseases School of Medicine, Johns Hopkins University 1550 Orleans St, Room 176, Baltimore, MD, USA 21231 Ph: +1-410-502-8230 Mobile:+1-4434545362
Abstract: Efficient control of tuberculosis (TB) requires development of strategies that can enhance efficacy of the existing vaccine Mycobacterium bovis Bacille Calmette Guerin (BCG). To date only a few studies have explored the potential of latency-associated antigens to augment the immunogenicity of BCG.
Abstract: Owing to its highly immunodominant nature and ability to induce long-lived memory immunity, ESAT-6, a prominent antigen of Mycobacterium tuberculosis, has been employed in several approaches to develop tuberculosis vaccines. Here, for the first time, we combined ESAT-6 based recombinant BCG (rBCG) and DNA vaccine (DNAE6) in a prime boost approach. Interestingly, in spite of inducing an enhanced antigen specific IFN-gamma response in mice, a DNAE6 booster completely obliterated the protection imparted by rBCG against tuberculosis in guinea pigs. Analysis of immunopathology and cytokine responses suggests involvement of an exaggerated immunity behind the lack of protection imparted by this regimen.
Abstract: The present invention provides a recombinant BCG over-expressing -crystallin protein for use in generating an immunogenic response in a subject against Mycobacterium and a vaccine formulation comprising the recombinant BCG. The invention further provides a prime boost vaccination approach against the Mycobacterium and a vaccination kit for the same.
Abstract: The present invention relates to recombinant BCG-Ag85C based immunization against TB. The invention also provides a method for developing a recombinant BCG strain that over expresses Ag85C (fbpC, Rv0129c) gene of Mycobacterium tuberculosis and also provides a method to assess the protective efficacy of recombinant Mycobacterium bovis BCG-Ag85C against Mycobacterium tuberculosis infection.
